Monitor Halozyme's next steps: appeal to the Federal Circuit, potential reissue/reexamination, and impact on the parallel district court litigation against Merck. The cancellation of this patent may weaken Halozyme's position in the broader patent family dispute.
HALO drugs
HALO drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $102.98entry
- T+1 · 6d ago −1.26%α −2.58% · $101.68
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
The PTAB issued a final written decision in PGR2025-00042, holding all challenged claims (1, 2, 5, and 7–33) of Halozyme's U.S. Patent 12,037,618 unpatentable for lack of written description, lack of enablement, and obviousness. The patent covers modified PH20 hyaluronidase polypeptides, which are central to Halozyme's drug delivery technology platform. This is a material loss for Halozyme, as the patent is part of a broader patent family asserted against Merck in a related district court litigation.
PTAB Trial Details
Key Facts
- Final Written Decision in PGR2025-00042 cancels all challenged claims (1, 2, 5, 7–33) of U.S. Patent 12,037,618 B2
- Patent covers modified PH20 hyaluronidase polypeptides used in drug delivery
- Petitioner Merck Sharp & Dohme LLC prevailed on all three grounds: written description, enablement, and obviousness
- Patent is part of a family of 15+ related patents asserted in Halozyme v. Merck (2:25-cv-03179 D.N.J.)
- Halozyme's market cap is $14.0B; the patent is core to its technology platform
Financial Impact
Loss of patent protection for a key platform technology; potential impact on licensing revenue and litigation leverage against Merck. Exact financial exposure not stated in the decision.
Risk Factors
- Patent cancellation may reduce Halozyme's bargaining power in licensing negotiations and ongoing litigation
- Related patents in the same family face similar validity challenges in other PGR proceedings
- Appeal to the Federal Circuit is possible but uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2025-00042-fwd-HALO |
Track record
15 reports on HALO
1 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +17.70% at T+20 after the Oct 15, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 9, 20268d ago PTAB Trial Bearish 6/10 Viewing Entry $102.98 Now $96.50 +6.29% settles Nov 17
- Nov 6, 202610d ago Press Release Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $103.63 to $100.27 Now $96.50 −6.88% ▼ −3.24% −5.84% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $124.54 to $131.18 Now $96.50 −22.51% ▲ +5.33% +4.62% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $124.83 to $128.50 Now $96.50 −22.69% ▲ +2.94% +3.38% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Oct 15, 20264w ago PTAB Trial Bearish 7/10 Entry $121.84 to $125.63 Now $96.50 +20.80% ▼ −3.11% −3.54% vs SPY
- Sep 18, 20268w ago 8-K Mixed 6/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Sep 17, 20268w ago Insider Cluster Neutral 2/10 Entry $112.45 to $113.90 Now $96.50 −14.18% ▲ +1.29% +0.02% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $106.12 to $106.92 Now $96.50 −9.07% ▲ +0.75% −0.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers